# US 2022/0031733 A1 · Composition for the treatment of the oral cavity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0031733 A1
- Document ID: US20220031733A1
- Status: Published application
- Kind: A1
- Application number: 17/276,503
- Filed: 2019-09-13
- Published: 2022-02-03
- Earliest claimed: 2018-09-18
- Assignees: Fadim S.R.L.
- Applicants: Fadim Ltd
- Inventors: Andrea Dalseno
- Web page: https://patentgrep.com/patent/US20220031733A1

## CPC

- A61K 31/728: Hyaluronic acid
- A61K 9/006: {Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays}
- A61K 36/61: Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
- A61K 47/14: Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A61K 47/22: Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A61K 47/36: Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A composition for the prevention and treatment of the oral cavity comprising hyaluronic acid and a Manuka-derived product is described. The composition of the invention stabilizes the hyaluronic acid protecting the same from the aggression of the hyaluronidase present in the oral cavity, in particular on the mucous membranes and on the gingival walls, thus increasing the overall efficacy and the therapeutic effect.

## Claims

### Claim 1

A method for treating a oral cavity disorder, the method comprising the topical administration to a subject in need thereof of a composition comprising hyaluronic acid, at least one fatty acid C10-C20 ester of ascorbic acid, and 0.1-4.8 wt % of a Manuka-derived product selected from Manuka honey, Manuka essential oil and mixtures thereof.

### Claim 2 (depends on 1)

The method of claim 1, wherein said hyaluronic acid and said Manuka-derived product are in a weight ratio of 5:1 to 1:300.

### Claim 3 (depends on 1)

The method of claim 1, comprising up to 5 wt % of said hyaluronic acid based on the weight of the composition.

### Claim 4 (depends on 1)

The method of claim 1, wherein said Manuka-derived product is Manuka honey.

### Claim 5 (depends on 4)

The method of claim 4, wherein said Manuka-derived product is Manuka honey having a number UMF® of 10+ to 20+, or a mixture of Manuka essential oil and Manuka honey having a number UMF® of 10+ to 20+, where UMF means Unique Manuka Factor.

### Claim 6 (depends on 1)

The method of claim 1, wherein said at least one fatty acid C10-C20 ester of ascorbic acid is selected from ascorbyl laurate, ascorbyl myristate, ascorbyl palmitate, ascorbyl stearate and mixtures thereof.

### Claim 7 (depends on 6)

The method of claim 6, wherein said hyaluronic acid and said at least one fatty acid C10-C20 ester of ascorbic acid are in a weight ratio of 50:1 to 1:100.

### Claim 8 (depends on 6)

The method of claim 6, comprising up to 5 wt % of said at least one fatty acid C10-C20 ester of ascorbic acid based on the weight of the composition.

### Claim 9 (depends on 1)

The method of claim 1, wherein said hyaluronic acid has a molecular weight of 800-2000 kDa.

### Claim 10 (depends on 1)

The method of claim 1, said composition being in the form of a unit dose comprising up to 50 mg of said Manuka-derived product.

### Claim 11 (depends on 10)

The method of claim 10, wherein said unit dose comprises 5-50 mg of Manuka honey or 0.2-2 mg of Manuka essential oil, or both.

### Claim 12 (depends on 10)

The method of claim 10, wherein said unit dose comprises up to 2 mg of said hyaluronic acid.

### Claim 13 (depends on 10)

The method of claim 10, wherein said unit dose comprises up to 2 mg of said at least one C10-C20 fatty acid ester of ascorbic acid.

### Claim 14 (depends on 1)

The method of claim 1, said composition being in the form of a solution, lotion, emulsion, suspension, gel, ointment, cream, paste, spray, or combinations thereof.

### Claim 15 (depends on 1)

The method of claim 1, for use in the prevention and treatment of oral cavity disorders, said disorders including gingivitis, periodontitis, pyorrhea, aphthae, recurrent aphthae, mucositis, stomatitis, gingival lesions, gingival ulcers, dryness, halitosis, bleeding and gingival retraction.
